secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001628280-25-023798
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q1 revenue up 30% YoY to $23.9M; net loss narrows to $0.4M
----------------------------------------------------------------------------

- Cell Processing revenue of $21.6M (+33% YoY), driven by biopreservation media demand from commercial therapies.
- GAAP net loss from continuing ops of $0.4M vs. $3.2M loss in Q1 2024; adjusted EBITDA of $5.7M (24% of revenue).
- FY 2025 revenue guidance reaffirmed at $95.5M-$99.0M, representing 16%-20% growth over 2024.
- Completed acquisition of PanTHERA CryoSolutions on April 4, 2025, adding novel cryopreservation IRI technology.
- Cash and marketable securities of $107.6M at quarter end; balance sheet supports organic and inorganic growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828025023798/0001628280-25-023798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828025023798/blfs-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer